Ontogeny, Inc. is pursuing biopharmaceutical and cell transplant opportunities based on newly understood aspects of developmental biology. Disease targets include Parkinson's, stroke, osteoporosis and infertility. The Company has two sizable corporate partnerships in place and raised $27 million in its most recent financing.

Founders: Daniel R. Passeri